Engineered immune cells aim to tame stubborn IBD
NCT ID NCT07544160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called ICG318 CAR-T for people with inflammatory bowel disease (IBD) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and calm the overactive immune response causing IBD. The main goal is to check safety, but researchers also hope to see if patients can achieve long-term remission without needing other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan people's hospital
Zhongshan, Guangdong, 528403, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Study aims to keep workers with chronic illnesses on the job
- Blood and stool tests could revolutionize IBD monitoring
- Hidden kidney risk in kids with IBD: new study investigates
- Ear zap for IBD? tiny study tests nerve stimulation for gut relief
- New study seeks better ways to diagnose and predict inflammatory bowel disease